Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P62495
UPID:
ERF1_HUMAN
Alternative names:
Protein Cl1; TB3-1
Alternative UPACC:
P62495; B2R6B4; D3DQC1; P46055; Q5M7Z7; Q96CG1
Background:
Eukaryotic peptide chain release factor subunit 1 (Eukaryotic RF1), also known as Protein Cl1 and TB3-1, plays a crucial role in terminating translation. It forms part of the eRF1-eRF3-GTP ternary complex, which binds to stop codons in the ribosomal A-site, ensuring accurate stop codon recognition and peptidyl-tRNA hydrolysis. Additionally, it is involved in the SURF complex, aiding in nonsense-mediated mRNA decay.
Therapeutic significance:
Understanding the role of Eukaryotic peptide chain release factor subunit 1 could open doors to potential therapeutic strategies.